Veradermics posts positive Phase 2 data for VDPHL01 in female pattern hair loss, paving the way for a pivotal readout

summarizeSummary

VDPHL01 hit its Phase 2 endpoints in female pattern hair loss, delivering robust hair count increases and high patient-reported improvement. The data boost confidence ahead of the pivotal Phase 2/3 readout in 1H 2027 and support a potential first-in-class oral approval.

check_boxKey Events · Product Development and Regulatory · MANE

• Phase 2 Hit in Female Hair Loss

  At Month 6, VDPHL01 4.5mg once or twice daily achieved mean non-vellus hair count increases of 22.7 and 23.3 hairs/cm², with 88.9% and 90.0% of patients reporting 'improved' or 'much improved' hair coverage.

• Clean Safety Profile

  No treatment-related serious adverse events or cardiac adverse events of special interest were observed; the most common side effects were hypertrichosis (21.4%) and peripheral edema (7.1%).

• Rapid Onset of Effect

  As early as Month 2—the earliest measured time point—63.2% of participants reported improvement in hair coverage.

• Pivotal Catalyst in 1H 2027

  Topline data from the registration-directed Phase 2/3 Study 306 in female pattern hair loss is expected in the first half of 2027; male confirmatory Phase 3 data (Study 304) is due in 2H 2026.

auto_awesomeAnalysis · MANE · Life Sciences

Veradermics announced positive topline results from its Phase 2 'Study 207' evaluating VDPHL01 in women with pattern hair loss. The drug demonstrated rapid, consistent hair growth alongside a favorable safety profile, positioning it as a potential first FDA-approved oral treatment for a market of 30 million U.S. women. These results de-risk the ongoing Phase 2/3 registration trial (Study 306) and reinforce the broader VDPHL01 franchise, which already has positive male data. With a strong cash position extending runway into 2030, the company is well-funded to execute its pivotal program.